- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00735410
Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2008/2009
A Phase III, Multicenter, Uncontrolled, Open-label Study to Evaluate Safety and Immunogenicity of Preservative Free, Inactivated Split Influenza Vaccine, Using the Strain Composition 2008/2009 When Administered to Adult and Elderly Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Hessen, Germany, 35033
- Site 1, 2 and 3
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ≥ 18 years of age, mentally competent, willing and able to give informed consent prior to study entry
- available for all the visits scheduled in the study and able to comply with all study requirements
- in good health as determined by: medical history physical examination clinical judgment of the investigator
Exclusion Criteria:
- They Have any serious (in the judgment of the investigator) disease, including but not limited to:
Cancer, except for localized skin cancer Advanced congestive heart failure Chronic obstructive pulmonary disease (COPD) Autoimmune disease (including rheumatoid arthritis) Acute or progressive hepatic disease Acute or progressive renal disease Severe neurological or psychiatric disorder Severe Asthma
- They have a history of any anaphylactic reaction and/or serious allergic reaction following a vaccination, a proven hypersensitivity to any component of the study vaccine (e.g., to ovalbumin, chicken protein, chicken feathers, influenza viral protein neomycin or polymyxin).
- Known or suspected (or have a high risk of developing) impairment/alteration of immune function (excluding that normally associated with advanced age) resulting for example from:
receipt of immunosuppressive therapy (any parental or oral cortical steroid or cancer chemotherapy/radiotherapy) within the past 60 days and for the full length of the study; Receipt of immunostimulants, Receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within the past 3 months and for the full length of the study, Suspected or known HIV infection or HIV-related disease.
- Known or suspected history of drug or alcohol abuse.
- They have a bleeding diathesis or conditions associated with prolonged bleeding time that in the investigator's opinion would interfere with the safety of the subject;
- Women who are pregnant or woman of childbearing potential unwilling to practice acceptable contraception for the duration of the study (21 days).
- Influenza vaccination or laboratory confirmed influenza within the last 6 months and more than one influenza vaccination within the past 12 months
- Within the past 4 weeks they have received:
another vaccine any investigational agent;
- Any acute or chronic infection requiring systemic antibiotic treatment or antiviral therapy within the last 7 days.
- They have experienced fever (i.e., axillary temperature ≥ 38°C) within the last 3 days
- Simultaneous participation in another clinical study.
- Any condition, which, in the opinion of the investigator, might prevent the subject from participation or interfere with the evaluation of the study objectives.
- Severely obese with Body Mass Index (BMI) > 35
- Site personnel involved in evaluation of safety and their immediate relatives are excluded from participation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
1 dose of Split influenza vaccine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluation of antibody response to each influenza vaccine antigen, as measured by haemagglutination inhibition (HI) test on Day 0 and on Day 21
Time Frame: 21 days (-1/+7)
|
21 days (-1/+7)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluation of safety of the influenza vaccine
Time Frame: 21 days (-1/+7)
|
21 days (-1/+7)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- V44P12S
- 2008-000887-18
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Seasonal Influenza, Vaccine
-
Novartis VaccinesCompleted
-
Novartis VaccinesCompletedSeasonal Influenza VaccineGermany
-
NovartisNovartis VaccinesCompletedSeasonal Influenza | VaccineGermany
-
VaxartCompletedSeasonal Influenza Preventative Vaccine PharmacodynamicsUnited States
-
University of PittsburghMerck Sharp & Dohme LLC; PfizerCompletedAdolescent HPV Vaccine | Adolescent Influenza VaccineUnited States
-
The Jackson LaboratoryNational Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaboratorsRecruitingAging | Influenza Vaccine | Vaccine Response | Dendritic CellUnited States
-
Universität des SaarlandesFederal Institute of Sport ScienceCompletedInfluenza Virus Vaccine Adverse Reaction | Influenza Vaccine Allergy
-
Butantan InstituteUniversity of Sao Paulo; Insituto Adolfo Lutz; Centro de Referencia e Treinamento...CompletedImmunocompromised Patients | Safety of Pandemic Influenza A (H1N1)Vaccine | Immunogenicity of Pandemic Influenza A (H1N1)VaccineBrazil
-
University of Southern CaliforniaUniversity of California, Los Angeles; National Institute on Aging (NIA); Los...Completed
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
Clinical Trials on Seasonal Influenza Vaccine
-
National Institute of Allergy and Infectious Diseases...The Emmes Company, LLCCompleted
-
Liquidia Technologies, Inc.Children's Hospital Medical Center, Cincinnati; AccelovanceCompleted
-
Center for Disease Prevention and Control of Beijing...Completed
-
National Institute of Allergy and Infectious Diseases...The Emmes Company, LLCCompleted
-
Bill & Melinda Gates Medical Research InstituteIqvia Pty LtdWithdrawn
-
Novartis VaccinesCompleted
-
Novartis VaccinesCompleted
-
Abramson Cancer Center at Penn MedicineRecruiting
-
Butantan InstituteCompletedRNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Influenza, Human | Orthomyxoviridae Infections | Physiological Effects of Drugs | VaccinesBrazil
-
NovartisNovartis VaccinesCompletedInfluenza | Seasonal InfluenzaUnited Kingdom